Truscreen Group Limited
TRU.ASXHealth Care
The development, manufacture and sale of cancer detection devices and systems
Market Data
$0.013
-0.1%$13.1M
-100000.0x
$-0.003
0.00%
-0.3%
Latest Earnings
FY 31 March 2026 Revenue and Results Guidance Achieved
28 April 2026
TruScreen achieved its FY2026 revenue guidance with product sales of NZ$2.4M (+41% YoY) and total revenue of NZ$2.8M (+29% YoY), though the company reported an expected loss of approximately NZ$2.2M similar to FY2025 due to investments in market expansion across Uzbekistan, India, Indonesia and Africa. The company is pursuing significant growth opportunities through UNITAID funding applications worth up to US$18.4M in potential revenue over three years, supported by positive clinical validation from a 15,000-patient study and expanding global distribution. Key points: Revenue guidance achieved with product sales growing 41% YoY to NZ$2.4M and total revenue up 29% YoY to NZ$2.8M; Expanded geographic presence with revenue spread across wider number of countries and distributor network established in Uzbekistan, India, Indonesia and selected African markets; Positive clinical validation from peer-reviewed BMC Cancer publication of 15,000-patient COGA study demonstrating effectiveness of AI-enabled TruScreen technology
Recent Announcements
Becoming a substantial holder
VEN CAPITAL PTY LTD became a substantial holder (5.42%).
FY 31 March 2026 Revenue and Results Guidance Achieved
TruScreen achieved its FY2026 revenue guidance with product sales of NZ$2.4M (+41% YoY) and total revenue of NZ$2.8M (+29% YoY), though the company reported an expected loss of approximately NZ$2.2M similar to FY2025 due to investments in market expansion across Uzbekistan, India, Indonesia and Africa. The company is pursuing significant growth opportunities through UNITAID funding applications worth up to US$18.4M in potential revenue over three years, supported by positive clinical validation from a 15,000-patient study and expanding global distribution. Key points: Revenue guidance achieved with product sales growing 41% YoY to NZ$2.4M and total revenue up 29% YoY to NZ$2.8M; Expanded geographic presence with revenue spread across wider number of countries and distributor network established in Uzbekistan, India, Indonesia and selected African markets; Positive clinical validation from peer-reviewed BMC Cancer publication of 15,000-patient COGA study demonstrating effectiveness of AI-enabled TruScreen technology
Results Guidance FY2026
TruScreen provided FY2026 guidance showing product sales revenue expected to reach NZ$2.4M (41% growth) but below market expectations of NZ$2.8M due to payment delays from Uzbekistan and deferred Zimbabwe orders. The company expects to maintain similar losses of ~NZ$2.2M as it invests in market expansion across multiple regions. Key points: Product sales revenue expected to grow 41% to NZ$2.4 million; Total revenue guidance shows 28% growth to NZ$2.7 million; Successful expansion of distributor network in Uzbekistan, India, Indonesia and African markets
Get real-time alerts for TRU
Receive AI-powered earnings summaries and instant notifications when Truscreen Group Limited releases results.
Register Free